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Introduction: The objective of this paper is to systematically review the existing evidence of
the effectiveness and safety profile of a long-acting inhaled muscarinic antagonist as add-on
therapy in patients with asthma that is uncontrolled despite inhaled corticosteroid (ICS) use.
Methods: With the assistance of two experienced research librarians, we searched Ovid
MEDLINE/PubMed (1946 to September 12, 2013), the Cochrane Library review, and the TRIP
database. The key search terms were “tiotropium and asthma.” The search was limited to human
data published in English. Included in the systematic review were all randomized controlled
trials that evaluated the efficacy of tiotropium in patients with asthma. The clinical trials had
to be at least 4 weeks in duration and to provide adequate information on clinically appropriate
end points in asthma care (eg, change in lung function, exacerbation rates, and/or ICS dosing).
Data on patient characteristics, study design, outcome measures, concomitant asthma medication, and adverse events were extracted from the full text of each included individual study.
Marked heterogeneity of study design precluded statistical pooling of results for a meta-analysis.
Consequently, only descriptive summaries of outcomes are provided.
Results: Our database search retrieved 149 citations. We found five randomized controlled trials in
humans that met our criteria for inclusion in the systematic review. We also found two open-label
uncontrolled trials that were considered in the discussion. Each of the five included studies met
the Consolidated Standards of Reporting Trials criteria for a well-designed randomized trial.
Discussion: The five clinical studies included in this systematic review focused on evaluating the
efficacy of tiotropium as add-on therapy to ICS or ICS in combination with a long-acting inhaled
β2-agonist (LABA) in patients with uncontrolled moderate to severe persistent asthma. Tiotropium maintained lung function when ICSs were tapered and when an LABA was discontinued.
Tiotropium improved lung function when added to ICS alone or ICS–LABA combination therapy.
In the only trial to have compared the addition of tiotropium with doubling the dose of ICS,
tiotropium provided significantly superior results. In trials in which the addition of tiotropium
was compared with salmeterol, the beneficial effects of these two bronchodilators were similar.
No safety concerns were found with use of tiotropium as add-on therapy.
Conclusion: Tiotropium may have a beneficial role in moderate to severe persistent asthma despite
use of an ICS or ICS and LABA. Use of tiotropium as add-on therapy poses no safety concerns.
Keywords: tiotropium, asthma, lung, inflammation, inhaled corticosteroid, LABA, LAMA
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Asthma is a chronic inflammatory airway disease.1 Airway inflammation in asthma
is characterized by bronchial wall infiltration by eosinophils, activated mast cells,
and T lymphocytes. Cytokines from T helper 2 cells and leukotrienes play key roles
in mediating airway inflammation. Also seen are goblet cell hyperplasia, mucus
gland hypertrophy, and airway mucus accumulation. Increased airway smooth
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muscle mass and reversible bronchoconstriction are other
important features of asthma. Airway inflammation, mucus
accumulation, and bronchospasm account for the symptoms
of shortness of breath, wheezing, cough, and chest tightness in asthma.1 Understanding asthma pathophysiology is
an important issue for health care practitioners in the US
because asthma prevalence increased from 7.3% in 2001 to
8.4% in 2010. In 2010, an estimated 25.7 million Americans
had asthma – 18.7 million adults aged 18 years and over and
7.0 million children aged 0–17 years.2
The ultimate goal of asthma management is to minimize
symptoms, prevent acute exacerbations, and avoid adverse
medication effects. The pathophysiologic features of
asthma explain why current US and international guidelines recommend the use of an inhaled corticosteroid
(ICS) and a short-acting inhaled β2-agonist (SABA) for
treatment of persistent asthma.3,4 ICSs can control airway
inflammation,5,6 and SABAs can manage acute symptoms
related to bronchospasm. To reduce the risk of drug-related
side effects, current asthma management guidelines recommend a stepwise treatment approach to achieving optimal
asthma control, with more aggressive ICS dosing reserved
for patients with more severe disease.3,4 However, prospective
studies have confirmed that a significant proportion of asthma
patients do not achieve asthma control, even with maximal
approved doses of ICS.7 In patients who do not respond to
ICS treatment alone, asthma guidelines recommend addition of another long-term controller, such as a long-acting
inhaled β2-agonist (LABA), a leukotriene-modifying agent
(LMA), theophylline, and/or an anti-immunoglobulin E
monoclonal antibody. Despite the addition of agents like
LABAs and LMAs to ICSs, many asthma patients still
remain both symptomatic and obstructed.8 There is clearly
a need for alternative medications with different modes of
action in asthma management. One intriguing option as an
add-on therapy for asthma patients not responding to ICSs
is an anticholinergic.
Tiotropium bromide is a long-acting inhaled muscarinic antagonist (LAMA). It has high potency as a selective
antagonist at the muscarinic acetylcholine (Ach) receptors.
Tiotropium rapidly dissociates from M2 Ach receptors but
slowly dissociates from M3 Ach receptors.9 Consequently,
tiotropium provides 24-hour bronchodilation as maintenance therapy in moderate to severe chronic obstructive
pulmonary disease (COPD).10,11 Tiotropium has also been
shown to reduce goblet cell metaplasia and airway smooth
muscle mass in allergen-challenged mice and guinea pigs.12,13
Early evidence of clinical benefit with LAMA therapy
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in asthma was identified in COPD patients with airway
hyper-responsiveness and concomitant asthma.14–16
The objective of this paper is to systematically review the
existing evidence of the use of tiotropium in patients with
uncontrolled asthma and to provide recommendations for its
potential role in the treatment of asthma. We sought to answer
the question what is the existing evidence of the effectiveness
and safety profile of an LAMA as add-on therapy in patients
with asthma that is uncontrolled despite ICS use?

Materials and methods
Search strategy and study selection
We adhered to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) criteria when performing this study.17 With the assistance of two experienced
research librarians, we searched Ovid MEDLINE/PubMed
(1946 to September 12, 2013), the Cochrane Library
review, and the TRIP database. The key search terms were
“tiotropium and asthma.” The search was limited to human
data published in English.
Abstracts of articles identified in the search were reviewed
independently by two of the authors. Articles meeting preidentified inclusion and exclusion criteria were selected for
evaluation in this systematic review. Disagreements about
inclusion of individual articles were resolved by consensus
or review by a third author. Included in the systematic review
were all randomized controlled trials that evaluated the
efficacy of tiotropium in patients with asthma. The clinical
trials had to be at least 4 weeks in duration and to provide
adequate information on clinically appropriate end points in
asthma care (eg, change in lung function, exacerbation rates,
and/or ICS dosing). Excluded were unpublished and ongoing
research, animal studies, reviews, case reports, case series,
editorials, and studies in COPD patients (with or without
asthma). The references of published articles identified in
the search were examined for additional studies appropriate
for inclusion in the review.

Data extraction and quality assessment
Data on patient characteristics, study design, outcome measures, concomitant asthma medication, and adverse events
were extracted from the full text of each included individual
study. The methodologic quality of the trials was evaluated
using criteria reported in the Consolidated Standards of
Reporting Trials (CONSORT) Statement.18 Marked heterogeneity of study design precluded statistical pooling of
results for a meta-analysis. Consequently, only descriptive
summaries of outcomes are provided.
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Results
Our database search retrieved 149 citations of which 93 were
excluded because they did not meet the inclusion criterion of
being specific to the effect of tiotropium in asthma (Figure 1).
An additional 37 citations were excluded because they did
not describe results of clinical trials in humans. Twelve other
citations were not included. Two were single-patient case
reports, one was in Japanese, six had duplicate information,
and three studies did not make a distinction between asthma
and COPD.
We found five randomized controlled trials in humans that
met our criteria for inclusion in the systematic review.19–23

One open-label study without a control was identified in the
database search.24 This study was not included in the systematic review but was considered in the discussion. Following
review of the references of the selected papers, an additional
open-label trial without a control group was identified.25
This study was not included in the systematic review but
was considered in the discussion. Summary descriptions of
the five publications that met inclusion criteria are provided
in Tables 1 and 2. Detailed descriptions of the five selected
studies are provided as follows.
Fardon et al 19 evaluated the ICS sparing ability of
t iotropium in patients with severe persistent asthma.

Citations identified from Ovid and PubMed (n=149)
Citations excluded (n=93)
Not specific to the analysis of tiotropium in asthma (n=93)

Citations specific to tiotropium in asthma (n=56)

Citations excluded (n=37)
Review articles (n=13), letters, comments, or expert opinion
(n=18) and animal studies with no clinical end points (n=6)

Citations describing results of tiotropium clinical experience (n=19)

Citations excluded (n=12)
Case reports (n=2), Japanese language (n=1),
duplicates (n=6), and trials that included COPD
patients (n=3)

Citations describing results of controlled clinical trials with tiotropium in asthma (n=7)

Citations excluded (n=2)
Open-label trials (n=2)

Total publications reviewed (n=5)
Figure 1 Selection process of citations.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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Inadequately controlled moderate
persistent asthma:
B16-Arg/Arg patients FEV1 ,90% for
patients on ICS–LABA or ,80% for patients
on ICS
Reversibility (.12% and 200 mL
#10 pack-year smoking
Severe persistent asthma:
FEV1 ,65% predicted
FVC ,80% predicted
Reversibility .5%
Nonsmokers

Uncontrolled severe persistent asthma:
FEV1 ,80% predicted despite high-dose
ICS and LABA
ACQ $1.5
,10 pack-year smoking

Inadequately controlled severe persistent
asthma:
FEV1 #80%
ACQ $1.5 despite high-dose ICS
and LABA
,10 pack-year smoking
One exacerbation requiring
oral CS in previous year
Inadequately controlled severe persistent
asthma:
FEV1 ,70% or symptoms .6 days/week or
nocturnal symptoms .twice/week
,10 pack-year smoking

Bateman
et al22

Kerstjens
et al21

Kerstjens
et al23

Randomized, three-way
double-blind, triple-dummy,
crossover

Randomized, double-blind,
placebo–controlled,
parallel-group

Randomized, double-blind,
placebo-controlled,
crossover

Randomized, double-blind,
placebo-controlled,
crossover

Randomized, double-blind,
double-dummy,
placebo-controlled,
parallel-group

Design

14 weeks

48 weeks

8 weeks

4 weeks

16 weeks

Duration

210

912

107

18

388

Size

Initial 4 weeks: ICS 160 μg daily (run-in)
Subsequent 14-week crossover periods:
Tiotropium 18 μg in morning
Salmeterol 50 μg twice daily
ICS 320 μg daily (double-dose ICS)

Tiotropium noninferior to salmeterol
and superior to double-dose ICS
regarding symptoms and lung function

Tiotropium improved lung function
and reduced exacerbations when
added to ICS–LABA

Tiotropium significantly improved lung
function when added to ICS – LABA

Tiotropium may offer small benefit
when added to salmeterol in stepping
down ICS with no effect on the
quality of life or subjective symptoms

Tiotropium superior to placebo and
noninferior to salmeterol in moderate
persistent asthma with B16-Arg/Arg
genotype

Initial 4 weeks: usual ICS dose (400–1,000 μg
daily) and 50 μg salmeterol twice daily (run-in)
Subsequent 16 weeks:
5 μg tiotropium daily in evening
50 μg salmeterol twice a day
Placebo
Initial 4 weeks: fluticasone 1,000 mcg daily
(run-in)
Subsequent 4-week crossover periods:
Fluticasone 500 μg all patients
Salmeterol and placebo
Salmeterol and tiotropium
Initial 2 weeks: usual dose of ICS and
LABA (screen)
Subsequent 8-week crossover periods:
Tiotropium 5 mcg in morning
Tiotropium 10 mcg in morning
Placebo
Initial 4 weeks: usual ICS ($800 μg) and
LABA (run-in)
Subsequent 48 weeks:
Tiotropium 5 μg daily in morning
Placebo group

Overall conclusion

Intervention

Abbreviations: ACQ, Asthma Control Questionnaire; CS, corticosteroid; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, long-acting inhaled β2-agonist.

Peters
et al20

Fardon
et al19

Inclusion criteria

Study

Table 1 Design summary of the reviewed articles

Befekadu et al
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Not stated but change in FEV1 and AM PEF
emphasized.
Significant improvements in AM PEF with
salmeterol–ICS (41.5 L/min, P,0.01) and
salmeterol–ICS–tiotropium (55.3 L/min, P,0.01).
Significant improvements in FEV1 with
salmeterol–ICS–tiotropium (0.17 L, P,0.05) but
not salmeterol–ICS. No differences between the
two treatments in change in AM PEF or FEV1
Peak FEV1 within 3 hours after dosing at end
of 8-week treatment.
5 μg tiotropium: peak FEV1 significantly higher
than placebo (139 mL difference, 95% CI:
96–181 mL). 10 μg tiotropium: peak FEV1
significantly higher than placebo (170 mL
difference, 95% CI: 128–213 mL).
There were no significant differences between
active treatments.

Fardon
et al19

Kerstjens
et al23

Coprimary end points were peak FEV1 difference
in tiotropium vs placebo after 3 hours of
administration and trough FEV1 response at
week 24.
In both trials there was a superior response to
tiotropium compared with placebo for peak
FEV1 (trial 1 difference of 86±34 mL, P=0.01;
trial 2 difference of 154±32 mL, P,0.001)
and trough FEV1 (trial 1 difference of 88±31 mL,

Change in mean weekly predose PEF:
Tiotropium: -3.9±4.87 L/min
Salmeterol: -3.2±4.64 L/min
Placebo: -24.6±4.84 L/min.
Tiotropium was superior to placebo
(P,0.05) but was noninferior to salmeterol
(estimated difference -0.78 L/min,
95% CI: -13.096 to 11.53, P=0.002).

Bateman
et al22

Kerstjens
et al21

Primary outcome

Study

Table 2 Results summary of the reviewed articles

Significant differences between 5 μg tiotropium and placebo
for trough FEV1 (difference of 86 mL, 95% CI: 41–132 mL) and
between 10 μg tiotropium and placebo (difference 113 mL,
95% CI: 67–159 mL).
Both treatment doses of tiotropium were superior to placebo in
peak FVC, trough FVC, and area under the curve for FVC during
the first 3 hours, and weekly AM and PM PEF. The 10 μg dose of
tiotropium resulted in significantly better AM and PM PEF than
the lower dose.
No significant differences in asthma symptoms, use of rescue
medications, and change in Mini AQLQ with either dose of
tiotropium or placebo.
Time to first severe asthma exacerbation increased in the
tiotropium group by 56 days, with overall 21% reduction
in exacerbations (P=0.03).
Small but inconsistent changes with tiotropium compared with
placebo in ACQ-7, AQLQ, symptom-free days recorded in the
electronic diary, and use of rescue medications.

Mean weekly PEF and FEV1 worse in the placebo group;
similar between salmeterol and tiotropium (P,0.01).
Rescue medication use, limitation of activities, and daytime asthma
symptoms maintained in active treatment groups but worsened
in the placebo group. Reduction of rescue medication use
statistically significant only in the salmeterol group.
No evidence of a treatment response in quality of life measures.
Number of asthma-free days slightly increased in the tiotropium
and salmeterol groups, more than placebo.
Salmeterol slightly superior regarding asthma-free days than
tiotropium (1.84 vs 1.34, respectively, 95% CI: -0.955 to -0.069).
RV and TLC were not altered by any treatment.
Addition of tiotropium to salmeterol–ICS reduced exhaled
NO by 2.86 ppb (P,0.05). No changes in quality of life or
symptoms.

Secondary outcome

Respimat

Respimat

Metered dose
inhaler

Respimat

Mode of delivery
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Adverse events reported in 73.5% and 80.3% of patients in
the tiotropium and placebo groups, respectively.
Serious adverse events reported in 8.1% of patients in the
tiotropium group and 8.8% in the placebo group.
The only individual adverse event reported in more than
2% of patients and more frequently in the tiotropium group
than placebo was allergic rhinitis. Drug-related cardiac
events were infrequent (0.4% in the tiotropium group and
0.2% in the placebo group). Blood pressure, pulse rate,

Adverse events in 40%, 42%, and 50% of patients
receiving placebo, 5 μg tiotropium, and 10 μg tiotropium,
respectively. Dry mouth reported by more patients in
the 10 μg tiotropium dose group.
Severe adverse events in 5 patients (all nonlifethreatening and nondrug related). No blood pressure,
pulse rate, ECG, or laboratory test abnormalities could
be attributed to the study drug or dose.

Not discussed directly.

Adverse events reported by 41.3%, 39.8%, and 41.8%
of patients in the placebo, tiotropium, and salmeterol
groups, respectively. Individual adverse event reporting
generally similar for the three treatment groups. Asthma
exacerbations reported in similar rates for the three
treatment groups. No cardiovascular events were
reported.

Safety

Dovepress
Tiotropium in asthma
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HandiHaler
Tiotropium was superior to double dose of ICS for PM PEF
(difference of 35.3 L/min, P,0.001), FEV1 (difference of
0.10 L, P=0.004), and daily symptom scores (difference
-0.11 points, P,0.001).
Tiotropium was noninferior to salmeterol in other lung
function and symptom assessments except for
prebronchidilator FEV1 (tiotropium superior with difference
of 0.11 L, P=0.003).
Peters
et al20

AM PEF: tiotropium was superior to double
dose of ICS (mean difference 25.8 L/min,
P,0.001). Tiotropium was noninferior to
salmeterol (difference of 6.4 L/min, P=0.26).

P=0.01; trial 2 difference of 110±30 mL,
P,0.001).

Secondary outcome
Primary outcome
Study

Table 2 (Continued)
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Abbreviations: ACQ, Asthma Control Questionnaire; AM, morning; AQLQ, Asthma Quality of Life Questionnaire; CI, confidence interval; ECG, electrocardiogram; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity;
ICS, inhaled corticosteroid; NO, nitric oxide; PEF, peak expiratory flow; PM, evening; RV, residual volume; TLC, total lung capacity.

and ECG abnormalities were balanced between the two
groups.
Three life-threatening events occurred in the tiotropium
group (2 asthma exacerbations and 1 cerebral infarction)
but none with placebo.
Individual adverse events not reported.
Asthma exacerbations occurred in 9 patients on
tiotropium, 16 patients on double-dose ICS, and
5 patients on salmeterol.
There were 12 serious adverse events, 3 in the
tiotropium group, 4 in the double-dose ICS group, and
4 in the salmeterol group.

Mode of delivery

Safety

Befekadu et al

I nclusion criteria for this clinical trial required that study
patients be adults with a clinically established diagnosis
of asthma and with .15% reversibility after an SABA
or a short-acting inhaled muscarinic antagonist (SAMA).
Inclusion criteria also required a forced expiratory volume
in 1 second (FEV1) of #65%. Patients were excluded if they
had had a recent exacerbation or had smoked at any time
during their life. The study was a double-blind, randomized, placebo-controlled, crossover study. Patients were
changed from their usual asthma medications to 1,000 µg
of fluticasone daily for a 4-week run-in period. Their dose
of fluticasone was then halved to 500 µg/day and an LABA
was added (125/25 µg per puff and two puffs twice daily). At
that point, patients entered a crossover phase in which they
were randomized, first, to the addition of either tiotropium
bromide (18 µg administered once daily from a metered dose
inhaler) or a matched placebo before, secondly, receiving
the other treatment. The crossover phases lasted 4 weeks
and there was no washout period between study phases.
A specific primary outcome measure was not identified in
this study. Twenty-six lifelong nonsmoking severe asthmatics with a mean FEV1 of 1.49 L (51% predicted) entered
the run-in phase, but only 18 patients completed the study.
Four weeks after patients were switched from fluticasone
1,000 µg/day to the lower dose of ICS with an LABA for
the run-in period, there were significant increases in morning
(AM) and evening (PM) peak expiratory flow (PEF). Four
weeks after switching to the combination of an ICS–LABA
with tiotropium there were significant improvements in
FEV1 (0.17 L; 95% confidence interval [CI]: 0.01–0.32;
P,0.05) and forced vital capacity (FVC) (0.24 L, 95%
CI: 0.05–0.43; P,0.05). The ICS–LABA–tiotropium combination also resulted in reduced exhaled nitric oxide levels
by 2.86 ppb (95% CI: 0.12–5.6; P,0.05). The increases in
lung function with the triple combination of ICS–LABA–
tiotropium were not significantly different from the changes
found with the ICS–LABA combination, though. Although
there were small improvements in subjective symptoms
of quality of life, measured by the Mini Asthma Quality
of Life Questionnaire (Mini AQLQ) after both crossover
phases, the changes were not significant. The small sample
size and the fact that eight of the participants dropped out
due to an asthma exacerbation were mentioned as possible
reasons for the failure of the study to detect improvement
in quality of life. The authors also evaluated acute changes
in lung function after single doses of an SABA with an
SAMA. There was a significant bronchodilator benefit after
the inhalation of albuterol and ipratropium, but the response
to short-acting inhaled bronchodilators did not predict the
Journal of Asthma and Allergy 2014:7
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response to tiotropium. Safety information was not provided
in this study.
Peters et al20 compared the benefit of tiotropium as
add-on therapy to an ICS with that obtained by either adding an LABA or doubling the ICS dose in patients with
uncontrolled persistent asthma. Patients were included if
they were nonsmokers (less than 10 pack-years per lifetime), were aged 18 years or older, had an FEV1 .40% of
the predicted value, and had a diagnosis of asthma confirmed by bronchodilator reversibility or bronchial hyperresponsiveness. The study was a three-way, double-blind,
triple-dummy, crossover trial. Patients entered a 4-week
run-in period during which they were treated with 160 µg
of beclomethasone daily. They were entered into the trial
if they had either an FEV1 #70% or daytime symptoms
for 6 or more days per week or night-time symptoms 2 or
more nights per week during the final 2 weeks of the run-in
period. The three crossover periods involved adding tiotropium (18 µg every AM from a dry powder inhaler), adding
salmeterol (50 µg twice daily by dry powder inhaler), or
doubling the ICS to 320 µg daily. Each treatment period
lasted 14 weeks with a 2-week washout phase between
treatment periods. The identified primary outcome measure
in this study was the AM PEF, and the primary hypothesis
was that the addition of tiotropium to ICS would provide
greater benefit than doubling the dose of ICS. Two hundred and ten severe asthma patients with a mean FEV1 of
2.31 L (71.5% predicted) met the entry criteria and were
randomized. Thirty-six participants dropped out during
the treatment phase due to withdrawal of consent, loss to
follow-up, drug-related adverse events, or miscellaneous
reasons. The use of tiotropium resulted in a superior
primary outcome compared with doubling the dose of an
ICS. There was a greater improvement in the primary outcome measure AM PEF with tiotropium compared with a
double dose of ICS, with a mean difference of 25.8 L/min
(P,0.001). Tiotropium also showed superiority in most
secondary outcomes. PM PEF was larger, with a difference
of 35.5 L/min (P,0.001); the proportion of asthma control
days was greater, with a difference of 0.079 (P=0.01); the
FEV1 before bronchodilation was larger, with a difference
of 0.10 L (P=0.004); and daily asthma symptom scores
were lower, with a difference of −0.11 points (P,0.001).
In the secondary outcome analysis, addition of tiotropium
to an ICS was found to be noninferior to salmeterol, as
measured by the AM PEF. Although the prebronchodilator
and postbronchodilator FEV1 responses favored tiotropium,
tiotropium was noninferior to salmeterol in other results,
including PM PEF, asthma daily symptom scores, and
Journal of Asthma and Allergy 2014:7
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sputum eosinophils. Interestingly, a small FEV1 decrease
in patients receiving albuterol in addition to the standing
dose of salmeterol suggested a tachyphylaxis effect for
β-agonists that was not found in the tiotropium group. Not
increasing the dose of ICS by more than a factor of two was
proposed as a potential weakness of the trial, together with
the short study duration (14 weeks) and the small sample
size. Although long-term safety issues were not assessed in
this trial, numerically more asthma exacerbations occurred
during the double-dose ICS treatment period than during the
tiotropium treatment period (n=16 versus [vs] n=9), with the
fewest occurring with salmeterol treatment (n=5).
Kerstjens et al21 sought to compare the efficacy and
safety of different doses of tiotropium in the Respimat®
inhaler (Boehringer Ingelheim Pharma GmbH and Co, KG,
Ingelheim, Germany) against placebo as add-on therapy in
patients with uncontrolled severe persistent asthma. Patients
included in this trial were aged 18 years and older and had at
least a 5-year history of asthma. They were required to have
a postbronchodilator FEV1 #80% and to have an Asthma
Control Questionnaire (ACQ) score of $1.5 despite treatment
with high-dose ICS and an LABA. Interestingly, patients were
allowed to remain on a stable dose of theophylline, LMA,
and oral corticosteroid throughout the study. Patients were
excluded if they had a smoking history of $10 pack-years or
a diagnosis of COPD. The authors conducted a randomized,
double-blind, crossover study with three 8-week treatment
periods. After a 2-week run-in period, eligible patients were
randomized to receive each of three treatments in a random
sequence for 8 weeks in a crossover design (5 µg or 10 µg of
tiotropium or matching placebo administered as two actuations once daily in the AM from the Respimat inhaler). There
was no washout phase between treatment periods. Throughout
the 24-week treatment period, participants recorded PEF and
FEV1 values twice daily at home using the Asthma Monitor
AM2+ and responded to daily questions in the electronic
diary component of this device. The primary end point was
peak FEV1 (obtained within 3 hours of dosing) at the end
of each treatment period. Of the 107 randomized patients,
100 completed all treatment periods. Peak FEV1 was significantly higher with 5 µg of tiotropium (difference 139 mL;
95% CI: 96–181 mL) and 10 µg (difference 170 mL; 95%
CI: 128–213 mL) than with placebo (both P,0.0001). Trough
FEV1 at the end of the dosing interval was also higher with both
doses of tiotropium than with placebo (difference with 5 µg of
86 mL [95% CI: 41–132]; difference with 10 µg of 113 mL
[95% CI: 67–159 mL], both P,0.0004). Although there
were numerically greater FEV1 responses with the 10 µg dose
of tiotropium than with the 5 µg dose compared with placebo
submit your manuscript | www.dovepress.com
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for both peak and trough FEV1, the differences in outcome
measures between the two active doses were not significant.
Across groups, no significant difference was noted in asthmarelated health status, rescue medication use, or symptoms
measured in the electronic diary. There was a trend for more
adverse events to be reported with the 10 µg tiotropium treatment group than with the placebo group. Patients receiving
the highest dose of tiotropium specifically reported more
complaints about dry mouth than the placebo group (6.8%
vs 1.0%). Serious adverse events and asthma exacerbations
were few and balanced among the treatment groups.
Bateman et al22 compared the efficacy and safety of
tiotropium as add-on therapy to patients with moderate
persistent asthma not adequately controlled by ICS therapy
alone against salmeterol and placebo. As a novel twist of this
study, the authors focused their study on a specific group of
asthma patients with the B16-Arg/Arg genotype. Patients
with a history of asthma with the B16-Arg/Arg genotype and
receiving maintenance therapy with ICS of 400–1,000 µg/day
of budesonide or equivalent were eligible for enrollment. The
main inclusion criteria were reversible airway obstruction
(improvement in FEV1 of at least 12% and 200 mL after
sequential inhalation of 80 µg of ipratropium bromide and
400 µg of salbutamol) and prebronchodilator FEV1 of 90%
of predicted value or less for patients previously receiving a
daily dose of at least 100 µg of salmeterol or 18 µg of formoterol and an ICS of 80% of predicted value or less for patients
previously receiving ICSs only. The main exclusion criteria
were smoking history (.10 pack-years), COPD, serious concomitant illnesses, and concomitant respiratory medications.
They conducted a double-blind, double-dummy, placebocontrolled, parallel-group trial. There was a 4-week run-in
period during which patients received 50 µg of twice-daily
salmeterol administered through a metered dose inhaler along
with their ICS. After the run-in period, patients were randomized to 16 weeks of treatment with tiotropium (two puffs of
2.5 µg daily in the PM through the Respimat inhaler), salmeterol metered dose inhaler (two puffs of 25 µg twice daily
plus tiotropium-matching placebo), or placebo (with both a
tiotropium and salmeterol matching placebo). The primary
end point was change in weekly AM (predose) PEF from
the last week of run-in period to the last week of treatment.
A total of 530 patients were eligible for the trial and 388 were
randomized. At baseline almost all patients were receiving
ICSs. The majority of patients in each treatment group were
also receiving an LABA. The prebronchodilator FEV1 was
between 68% and 70% for the three treatment groups. There
was, on average, between a 24% and 28% increase in FEV1
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after ipratropium and albuterol. The AM PEF was maintained
with tiotropium (−3.9±4.87 L/min change from run-in)
and salmeterol (−3.2±4.64 L/min change from run-in), but
the AM PEF decreased with placebo (−24.6±4.84 L/min
from run-in). Both active treatments provided significantly
superior effects on AM PEF compared with placebo. The
tiotropium effect was noninferior to salmeterol. Weekly FEV1
measures showed the same treatment effects as the AM PEF.
Surprisingly, little evidence of treatment effect with tiotropium and salmeterol was found in asthma symptoms, rescue
medication use, and the Mini AQLQ. In general, adverse
event reporting was comparable across treatment groups.
There were numerically more asthma exacerbations with
salmeterol treatment (n=4) than with either placebo (n=1)
or tiotropium (n=0).
In two large replicate studies, Kerstjens et al23 compared
the effect of adding 5 µg of tiotropium each AM to placebo on
lung function and exacerbations in poorly controlled asthma
patients already receiving ICS and LABA. Included patients
were aged between 18 years and 75 years and had a 5-year
or longer asthma history. Other inclusion criteria consisted
of an ACQ score of 1.5 or higher, a postbronchodilator
FEV1 #80% predicted, and a postbronchodilator FVC #70%
predicted despite daily therapy with high-dose ICS and
LABA. Included patients also had at least one asthma exacerbation in the preceding year that required treatment with
systemic corticosteroids. Main exclusion criteria consisted
of a pre-existent diagnosis of COPD, serious coexisting illness, and concurrent use of anticholinergic bronchodilators.
Patients with a $10 pack-years smoking history and who
had smoked within the past year were also excluded. The
study was a randomized, double-blind, placebo-controlled,
parallel-group design. After a 4-week screening period,
patients were randomized to treatment with either tiotropium
(5 µg daily) or placebo, both administered by the Respimat
Soft Mist Inhaler in the AM for 48 weeks, which made it
the longest trial carried out on this subject. The primary
outcomes were the peak FEV1 (measured within 3 hours of
treatment) and trough FEV1 at week 24 expressed as change
from baseline. In the two studies, 912 eligible patients were
randomized. At 24 weeks, the mean change in the peak FEV1
from baseline was greater with tiotropium than with placebo
in the two trials: a difference of 86±34 mL in trial 1 (P=0.01)
and 154±32 mL in trial 2 (P,0.001). Similar significant
differences in favor of tiotropium treatment were found
with the trough FEV1. The effects of tiotropium continued
throughout the entire 48 weeks of the study. In addition, the
addition of tiotropium increased the time to the first severe
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exacerbation (282 days vs 226 days) with an overall reduction of 21% in the risk of a severe exacerbation (hazard ratio
0.79; P=0.03). Consistent differences between tiotropium and
placebo treatment on the ACQ, the AQLQ symptom-free
days, and rescue medication use were not found, however.
Adverse event reporting was slightly lower with tiotropium
than with placebo. No differences were found between the
groups in cardiac adverse events and serious adverse events.
Treatment with tiotropium was associated with a slightly
higher complaint rate of dry mouth.
We performed an assessment of the methodologic quality
of the five studies, and we assessed the consistency and adherence of the five trials to the CONSORT. We concluded that
each study met the CONSORT criteria for a well-designed
randomized trial.18

Discussion
Tiotropium is an inhaled long-acting anticholinergic currently approved in the US for once-daily maintenance
treatment of bronchospasm associated with COPD.26 It has
been proven to be an effective bronchodilator and to reduce
the frequency of COPD exacerbations.10,11 Despite the
well-studied pharmacology of tiotropium, its role in asthma
remains unproven. The drug is currently not approved for
non-COPD obstructive airway disease. In this systematic
review we found that adding tiotropium to pre-existing
therapy with only an ICS or an ICS–LABA combination
resulted in significant improvements in lung function. There
was also evidence from one study suggesting a reduction in
exacerbations in patients with uncontrolled severe asthma.
These observations are supported by findings in open-label,
uncontrolled studies. The findings are consistent with the
known effect of a muscarinic antagonist and its mechanism
of action in the context of asthma pathophysiology.
The five clinical studies included in this systematic
review focused on evaluating the efficacy of tiotropium as
add-on therapy to ICS or ICS in combination with an LABA
in patients with uncontrolled moderate to severe persistent
asthma. Tiotropium maintained lung function when ICSs
were tapered and when an LABA was discontinued.19,22
Tiotropium improved lung function when added to an ICS
alone or an ICS–LABA combination therapy.20–23 In the
only trial to have compared the addition of tiotropium with
doubling the dose of ICS, tiotropium provided significantly
superior results.20 In trials in which the addition of tiotropium
was compared with salmeterol, the beneficial effects of these
two bronchodilators was similar.20,22 Although the improvements in lung function appeared to be clinically meaningful,
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these clinical trials failed to show that tiotropium provided
consistent and clinically relevant improvements in respiratory
symptoms, rescue medication use, or quality of life. Perhaps
the failure to show symptomatic improvements was a function of study size. In the one report powered sufficiently to
assess any change in the symptomatic burden of asthma,
the addition of tiotropium resulted in an overall reduction of
exacerbations and an increase in the time between them.23
Overall, the consistent improvement in lung function with
the addition of tiotropium should probably lead to US Food
and Drug Administration approval of tiotropium as add-on
therapy for patients with uncontrolled moderate to severe
persistent asthma already on ICSs. Unfortunately, the available information does not enable health care providers to
determine whether an individual patient might respond more
to tiotropium or an LABA as add-on therapy.27
Although excluded from the systematic review, the two
open-label trials we found on this topic support the findings
of the other five studies. Iwamoto et al24 added tiotropium to
17 patients with severe persistent asthma who were receiving
high-dose ICSs. Many of these patients were also taking an
LABA and/or oral corticosteroids. The study was an openlabel, uncontrolled design. They found that use of tiotropium
for 4 weeks significantly improved FEV1 (P=0.001). Of note,
the percentage of eosinophils in the induced sputum of the
participants was inversely correlated with the change in FEV1,
whereas the neutrophil proportion was directly correlated with
an increase in FEV1. This suggested that the noneosinophilic
sputum profile may separate responders vs nonresponders
to tiotropium therapy. A similar interest in distinguishing
responders from nonresponders was reflected in the study
conducted by Park et al.25 They studied 138 patients with
severe persistent asthma who had reduced lung function despite
high-dose ICSs and LABA. Tiotropium, administered as 18 µg
daily from a dry powder inhaler, was added to this regimen.
Lung function tests were evaluated every 4 weeks for a minimum of 12 weeks. Responders were defined as having a .15%
(or .200 mL) improvement in FEV1, with a sustained effect
lasting at least 8 successive weeks. Forty-six of the 138 patients
(33.3%) responded to tiotropium treatment. Logistic regression
analysis (controlled for age, sex, and smoking status) showed
that Arg16Gly in ADRB2 (P=0.003, odds ratio 0.21, 95%
CI: 0.07–0.59) in a minor allele-dominant model was significantly associated with the response to tiotropium.
Improved lung function (increased FEV1 and PEF) in
asthma with tiotropium can be explained by its mechanism of
action in the context of asthma pathophysiology. The major
bronchi (the site of bronchoconstriction in asthma) have the
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densest population of cholinergic nerves in the respiratory
tract. Bronchoconstriction is mainly mediated through cholinergic mechanisms in humans.27 Stimulation of cholinergic
fibers leads to activation of M3 Ach receptors in the airway
smooth muscle, which, in turn, causes bronchoconstriction
and mucus secretion. Tiotropium is an effective M3 Ach
receptor antagonist. Cholinergic stimulation may also have
influences in addition to controlling airway smooth muscle
contraction. Cholinergic pathways influence mucus secretion
and possibly airway inflammation. It has been speculated
that tiotropium might be able to affect airway remodeling
in asthma through these mechanisms.28,29
Only four of the clinical trials reported complete information on adverse events related to tiotropium use. In general,
similar total and individual reporting of adverse events was
described for tiotropium and salmeterol compared with
placebo. The only exception was that patients receiving higher
doses of tiotropium (eg, 10 µg) tended to report dry mouth
more frequently.21 The cardiovascular safety profile of tiotropium is of particular interest. In COPD patients, Verhamme
et al30 found that tiotropium administered 5 µg daily by the
Respimat Soft Mist Inhaler was associated with about a
30% increase in mortality compared with a comparable dose
of tiotropium administered by a dry powder inhaler. The
mortality association was strongest for cardiovascular and
cerebrovascular death. However, it remains unclear whether
this association is causal or due to residual confounding by
COPD severity. A more recent study, also performed in COPD
patients, found that tiotropium administered by the Respimat
Soft Mist Inhaler at a dose of 5 µg or 2.5 µg had a safety profile
similar to that of tiotropium given by dry powder inhaler at a
dose of 18 µg.31 The 48-week studies reported by Kerstjens
et al23 described no deaths and few cardiovascular safety
events in asthma patients using tiotropium administered by
the Respimat Soft Mist Inhaler.
There are strengths and limitations to this systematic
review. Although the number of studies included was small,
the studies were of high quality. They were randomized and
controlled. All studies met the CONSORT criteria for reporting of randomized trials. There were limitations, though, in
the five studies. One study was small, with only 18 completed
patients.19 Two studies were short, only 4 and 8 weeks.19,21
Consequently, information available regarding sustainability
of benefit is somewhat limited.23 The trials were a mixture of
crossover and parallel-group design, making integration of efficacy results impractical. There may still be unresolved issues
regarding the appropriate dosing of tiotropium in the treatment
of asthma. Different inhalation devices (with different doses)
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were used to administer tiotropium, metered dose inhaler,19
dry powder inhaler,20 and the Respimat Soft Mist Inhaler.21–23
One study compared the effect of 5 µg of tiotropium from
the Respimat vs 10 µg. The effects on lung function of the
10 µg tiotropium dose tended to be greater, but there was also
a higher reporting rate of dry mouth with the larger dose. It
is unclear whether the 10 µg tiotropium dose might provide
additional benefits with long-term use, such as a further reduction in exacerbation rates. Although two of the studies using
tiotropium in the Respimat had patients self-administer their
dose in the AM, one of the studies required PM dosing.21–23 It
is difficult to determine from these studies whether there might
be greater benefits of PM vs AM dosing.
There was limited information available from these studies regarding the anti-inflammatory benefits of tiotropium
in uncontrolled asthma. Fardon et al19 found that addition
of tiotropium was associated with a significant reduction
in exhaled nitric oxide levels, but Peters et al32 found that
immunoglobulin E levels, sputum eosinophil counts, and
exhaled nitric oxide levels were not predictive of a clinical
response to tiotropium. Similarly, reversibility testing to
either an SABA or an SAMA was not helpful in identifying
patients who would have a beneficial tiotropium response.19
Because all studies required SABA reversibility as an
inclusion criterion, it is unclear whether an uncontrolled
asthma patient with moderate to severe persistent disease
but without reversibility would have a beneficial response
to tiotropium.
In summary, there may be a beneficial role for tiotropium
in moderate to severe persistent asthma patients who are
uncontrolled despite use of an ICS or an ICS and an LABA.
However, it remains to be determined whether the spirometric changes will ultimately reciprocate in long-term
symptom improvement. The currently available literature
lays a sound foundation for further studies to be designed
with particular focus on the asthma population. An important
issue will be to determine whether patterns of genotypes,
physiology, or inflammatory markers can be identified that
would identify patients with the maximal potential benefit
from treatment with tiotropium in addition to currently
approved therapy.
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